As part of Myeloma Patients Europe’s (MPE) ongoing work to ensure that the patient voice is fully represented, and to strengthen organizations’ and individuals’ ability to advocate effectively, in 2017 MPE created the Advocate Development Program (ADP). The ADP is a 12-month training programme designed to develop participants’ advocacy knowledge and skills to better serve patients locally, nationally, and across Europe. Through the course, participants improve their understanding of clinical research and development, mechanisms of accessing diagnostics and drugs, interaction with stakeholders including clinicians and industry, and the basics of evidence-based advocacy.
The ADP combines virtual and in-person lectures to educate advocates on the disease and treatment of myeloma and AL amyloidosis as well as the entire drug development process. Participants will learn from experts in their fields to understand the research, development, and regulatory processes and how advocates can influence and shape these to improve patient experiences and outcomes. In addition to monthly sessions, the programme includes participation in important myeloma scientific meetings in Europe (attendance sponsored by MPE) such as the European Haematology Association (EHA) Annual Meeting and the European Cancer Summit.
Who should apply for the ADP?
Patients, carers, advocates, and community members who are interested in developing professional advocacy skills in the fields of myeloma and AL amyloidosis and who are committed to improving outcomes for patients across Europe.
Find the requirements applicants must meet and fill in the form here before October 31, 2020.